Search Results

Eko Health, a pioneer in applying artificial intelligence for early detection of heart and lung diseases, announced it has raised $41 million in Series D financing.

FIGS, Inc. (NYSE: FIGS), the direct-to-consumer healthcare apparel and lifestyle brand, and Eko Health, Inc. (“Eko”), a leading innovator in digital health technology for heart and lung disease detection, today announced the launch of the FIGS | Eko CORE 500™ Digital Stethoscope.

Astellas Pharma Inc. and Eko Health Inc. announced today that they have entered into a License & Supply Agreement for the global supply and license of Eko’s latest digital stethoscope.

Data from the REAL-PE study was presented at TCT, the annual scientific symposium of the Cardiovascular Research Foundation, demonstrating that patients treated for pulmonary embolism with the Boston Scientific EKOS™ Endovascular System had lower rates of adverse events, including statistically significant lower rates of major bleeding, within seven days following their procedure compared to the Inari FlowTriever® System.

Eko, a digital health company applying artificial intelligence (AI) in the fight against heart and lung disease, today announced the launch of the SENSORA™ Cardiac Disease Detection Platform.

Eko Health announces FDA clearance for its Low EF detection AI. For the first time, U.S. healthcare providers can now detect Low EF, a key heart failure indicator, in 15 seconds using an Eko stethoscope during a routine physical examination.

Eko, a digital health company advancing heart and lung disease detection, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Eko Murmur Analysis Software (EMAS) for detecting and characterizing murmurs found in adults and pediatric patients.

Eko, a digital health company advancing heart and lung disease detection, has been named to Fast Company’s annual list of the World’s Most Innovative Companies for 2022 in the Medical Device category.

Eko announced that the Imperial College of London, in conjunction with the UK National Health Service, published a study1 which highlights Eko’s ability to screen patients for heart failure in seconds with AI during physical exams.